VEGF-targeting therapy for breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Medical Research

Background:

• Vascular Endothelial Growth Factor (VEGF) is implicated in endothelial cell function.
• VEGF plays a significant role in both normal physiology and pathological conditions, including human breast cancer.
• Preclinical and clinical evidence highlights VEGF's importance in breast cancer progression.

Purpose of the Study:

• To review the role of VEGF in human breast cancer.
• To discuss the development and clinical trials of anti-VEGF agents for breast cancer.
• To highlight the success of bevacizumab in metastatic breast cancer treatment.

Main Methods:

• Review of preclinical and clinical evidence regarding VEGF in breast cancer.
• Analysis of clinical trial data for anti-VEGF therapies.
• Examination of the first large, prospective randomized trial of anti-VEGF therapy in metastatic breast cancer.

Main Results:

• The first large, prospective randomized trial demonstrated the benefit of adding bevacizumab to paclitaxel in front-line metastatic breast cancer.
• Numerous anti-VEGF agents are currently under investigation for breast cancer treatment.
• Adjuvant therapy trials for anti-VEGF agents are in development.

Conclusions:

• Anti-VEGF therapy, exemplified by bevacizumab, has shown clinical benefit in metastatic breast cancer.
• The success of initial trials has spurred further development of VEGF-targeting agents.
• Further research is needed to address remaining questions regarding VEGF biology and the clinical development of these agents in breast cancer.